Clinical trial NCT06550947: ALDOA Expression in Bladder Urothelial Carcinoma
Official title: Immunohistochemical Expression and Prognostic Significance of ALDOA in Bladder Urothelial Carcinoma.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Bladder Urothelial Carcinoma
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-08-13
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will be conducted using formalin fixed paraffin embedded blocks of fifty cases of urothelial carcinomas . These blocks will be obtained from laboratory archives of the Pathology Department, Assiut University Hospital, Faculty of Medicine. Clinical data for this study will be obtained from laboratory archives of the pathology department, Assiut University Hospital, Assiut University.

Brief summary: 1. Study the immunohistochemical expression of ALDOA in bladder urothelial cancer.
2. Correlate between ALDOA expression in specimens and different cilnicopathological factors.
3. Correlate between ALDOA expression and urothelial cancer prognosis and survival.

Detailed description: Bladder cancer is the 7th most prevalent malignancy and the 13th cause of cancer related death worldwide1. In Egypt, it's the third most common tumor2.

The most common histologic subtype of bladder cancer is urothelial carcinoma3. Bladder cancer is divided according to absence or presence of muscle invasion into non-muscle invasive bladder cancer and muscle invasive bladder cancer 3.

Despite the advance in diagnosis and development of therapeutic options of urothelial cancer, the recurrence and progression rate remains high4.

The conventional histopathological evaluation of urothelial cancer is vital for diagnosis and prediction of patient's prognosis. However, it doesn't fully reflect the biological behavior of the tumor or the clinical outcome of the patient5.

Under hypoxic conditions, cancer cells produce ATP by glycolysis, which provide energy for tumor proliferation and dissemination6,7. Glycolytic enzymes are abnormally activated in cancer cells8,9. Thus, several studies have identified glycolytic enzymes or related metabolic pathways as potential drug targets. One of the typical glycolytic enzymes is Aldolase A (ALDOA) 6 which is the most abundant glycolytic enzyme detected in tumors10.

Several studies have identified ALDOA as an oncogene in different types of malignancy 6,8,10-12. The oncogenic potential of ALDOA contributed to its ability to stimulate DNA synthesis and accelerate S phase in tumor cell cycle6-8.

In addition, studies have shown that ALDOA promotes tumor cell invasion by negative regulation of E-cadherin and by activation of MAPK, AKT and EGFR signaling pathways7,11,13.

Thus, increased expression of ALDOA in tumor predicts a bad prognosis and poor survival of patients13-15.

Eligibility criteria: Inclusion Criteria:

* All cases diagnosed as bladder urothelial cancer with known follow-up data and presence of muscle proper detected in the specimens.

Exclusion Criteria:

1. Subtypes of bladder cancer other than urothelial carcinoma subtype.
2. Cases of urothelial carcinoma without known follow up data.
3. Cases of urothelial carcinoma without muscle proper detected in the specimen.

Primary outcomes:
measure: Evaluate the immunohistochemical expression of ALDOA in bladder urothelial carcinoma.
timeFrame: Baseline
Secondary outcomes:
measure: Evaluate relation between ALDOA expression and cilnicopathological features and patient survival.
timeFrame: Baseline
Other outcomes:
Locations:
Study officials:
affiliation: Head of Pathology Department
name: Dalia Elsers, Professor
role: STUDY_DIRECTOR
References: